A head-to-head comparison study between basal insulin and GLP-1RA compound preparations and premixed insulin is released

At the ADA annual meeting, Sanofi initiated the world's first head-to-head study comparing basal insulin and glucagon-like receptor agonists (iGlarLixi) with premixed insulin-SoliMix results were announced

The SoliMix study included basal insulin combined with 1 to 2 oral hypoglycemic agents for the treatment of type 2 diabetes (T2DM) patients with poor blood sugar control, and divided them into basal insulin GLP-1RA compound preparations (insulin glargine and risena The peptide fixed-ratio compound preparation, iGlarLixi) treatment group and the premixed insulin (biphasic insulin aspart 30, BIAsp 30) treatment group, and then the investigator conducted an overview of the two main research endpoints and multiple key secondary research endpoints of the study.

The SoliMix study confirmed that compared with premixed insulin, iGlarLixi has non-inferiority in reducing glycated hemoglobin (HbA1c) levels, and has superiority in weight impact (primary study endpoint)

The SoliMix study also confirmed that compared with premixed insulin, patients treated with iGlarLixi had a higher blood glucose standard (HbA1c<7%) and did not gain weight; the proportion of patients who met the blood sugar standard, did not gain weight and did not develop hypoglycemia was also higher.

Julio Rosenstock, lead author of the SoliMix study and director of the Dallas Diabetes Research Center in Medical City, Dallas, Texas, said: “Worries about hypoglycemia and weight gain are major obstacles to advancing complex insulin treatment regimens.

Another analysis result of the SoliMix study also found that compared with premixed insulin, iGlarLixi had a greater degree of improvement in patient reporting outcomes at week 26

TRIM-D results showed that compared with patients using premixed insulin, patients treated with iGlarLixi had greater improvements in compliance, diabetes management, and mental health3

GTEE results showed that after treatment with iGlarLixi, the rate of patients reporting complete diabetes control was about twice that of the premixed insulin treatment group.

Note: The original text has been deleted

references:

Rosenstock, J.

Rosenstock, J.

Polonsky, W.

Yongze Li, Di Teng, Xiaoguang Shi, et al.